SV2016005186A - Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 - Google Patents

Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4

Info

Publication number
SV2016005186A
SV2016005186A SV2016005186A SV2016005186A SV2016005186A SV 2016005186 A SV2016005186 A SV 2016005186A SV 2016005186 A SV2016005186 A SV 2016005186A SV 2016005186 A SV2016005186 A SV 2016005186A SV 2016005186 A SV2016005186 A SV 2016005186A
Authority
SV
El Salvador
Prior art keywords
piridyl
bicyclic
fused
ring
compounds derived
Prior art date
Application number
SV2016005186A
Other languages
English (en)
Inventor
Nicole Buschmann
Robin Alec Fairhurst
Pascal Furet
Thomas Knöpfel
Catherine Leblanc
Robert Mah
Pierre Nimsgern
Sebastien Ripoche
Lv Liao
Jing Xiong
Xianglin Zhao
Bo Han
Can Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SV2016005186A publication Critical patent/SV2016005186A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

LA PRESENTE INVENCIÓN PROPORCIONA UN COMPUESTO DE LA FÓRMULA (I) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO: (VER FORMULA); UN MÉTODO PARA FABRICAR DICHO COMPUESTO, Y SUS USOS TERAPÉUTICOS. LA PRESENTE INVENCIÓN ADEMÁS PROPORCIONA UNA COMBINACIÓN DE AGENTES FARMACOLÓGICAMENTE ACTIVOS Y UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE DICHO COMPUESTO
SV2016005186A 2013-10-25 2016-04-25 Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 SV2016005186A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013086003 2013-10-25
CN2014088094 2014-10-03

Publications (1)

Publication Number Publication Date
SV2016005186A true SV2016005186A (es) 2016-11-21

Family

ID=52003015

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2016005186A SV2016005186A (es) 2013-10-25 2016-04-25 Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4

Country Status (27)

Country Link
US (3) US9266883B2 (es)
EP (1) EP3060563B1 (es)
JP (3) JP6203954B2 (es)
KR (1) KR101862493B1 (es)
CN (1) CN105683188B (es)
AP (1) AP2016009156A0 (es)
AU (1) AU2014338549B2 (es)
BR (1) BR112016008276B1 (es)
CA (1) CA2927252C (es)
CL (1) CL2016000922A1 (es)
CR (1) CR20160191A (es)
DO (1) DOP2016000094A (es)
EA (1) EA028819B1 (es)
ES (1) ES2682493T3 (es)
HK (1) HK1222388A1 (es)
IL (2) IL244819B (es)
MX (2) MX367723B (es)
NI (1) NI201600058A (es)
PE (1) PE20160546A1 (es)
PH (1) PH12016500756A1 (es)
PL (1) PL3060563T3 (es)
PT (1) PT3060563T (es)
SG (1) SG11201602183QA (es)
SV (1) SV2016005186A (es)
TN (1) TN2016000115A1 (es)
TR (1) TR201810944T4 (es)
WO (1) WO2015059668A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091096A1 (es) 2007-12-10 2009-08-25 Novartis Ag Compuestos organicos
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EA201492005A1 (ru) * 2012-05-15 2015-04-30 Новартис Аг Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
EP3822273B1 (en) 2012-06-13 2024-04-10 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
RS62233B1 (sr) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitori receptora fibroblast faktora rasta
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN110028491B (zh) 2013-10-25 2022-02-11 缆图药品公司 纤维母细胞生长因子受体抑制剂
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
TN2017000083A1 (en) 2014-10-03 2018-07-04 Sanofi Sa Fused pentacyclic imidazole derivatives
US20180185341A1 (en) 2014-10-03 2018-07-05 Novartis Ag Use of ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
CN107787226A (zh) * 2015-03-25 2018-03-09 诺华股份有限公司 药物组合
KR20170114254A (ko) * 2016-03-24 2017-10-13 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN108884097B (zh) 2016-05-20 2021-05-28 浙江海正药业股份有限公司 嘧啶类衍生物、其制备方法和其在医药上的用途
WO2017198149A1 (zh) * 2016-05-20 2017-11-23 江苏豪森药业集团有限公司 Fgfr4抑制剂、其制备方法和应用
KR20190038485A (ko) * 2016-05-27 2019-04-08 항저우 인노게이트 파마 컴퍼니 리미티드 Fgfr4 저해제인 헤테로 고리 화합물
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
CN109563091B (zh) * 2016-08-12 2022-04-29 江苏豪森药业集团有限公司 Fgfr4抑制剂及其制备方法和应用
WO2018049233A1 (en) 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
MA46712A (fr) 2016-11-02 2019-09-11 Novartis Ag Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire
CN108264510A (zh) 2017-01-02 2018-07-10 上海喆邺生物科技有限公司 一种选择性抑制激酶化合物及其用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR20200083448A (ko) 2017-09-05 2020-07-08 바이오아르디스 엘엘씨 방향족 유도체, 그의 제조 방법 및 그의 의학적 응용
CN111164075A (zh) * 2017-09-20 2020-05-15 北京加科思新药研发有限公司 用作fgfr4抑制剂的稠环衍生物
WO2019085927A1 (zh) * 2017-10-31 2019-05-09 江苏豪森药业集团有限公司 Fgfr4抑制剂的盐、晶体、制备方法及其用途
CN110225913B (zh) * 2017-10-31 2021-10-15 江苏豪森药业集团有限公司 Fgfr4抑制剂晶型及其制备方法
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物
CN109928968B (zh) * 2017-12-15 2021-11-05 成都华健未来科技有限公司 一类制备抗癌药物的中间体
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CN111285871A (zh) * 2018-07-05 2020-06-16 成都华健未来科技有限公司 一种脲类化合物的新型晶型产品及制备方法
CN111285869A (zh) * 2018-07-05 2020-06-16 成都华健未来科技有限公司 脲类化合物的新型晶型产品及制备方法
TWI723480B (zh) * 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CA3141474A1 (en) * 2019-05-21 2020-11-26 Westrock Packaging Systems, Llc Flexible pitch product metering system
WO2020257527A1 (en) * 2019-06-21 2020-12-24 Terns, Inc. Compounds for inhibiting fgfr4
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN113072550B (zh) * 2020-01-06 2023-08-08 周龙兴 一种高选择性成纤维细胞生长因子受体抑制剂和应用
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4226945A1 (en) 2020-10-05 2023-08-16 Chiome Bioscience, Inc Medicine for treating cancer
CN116528866A (zh) * 2020-11-02 2023-08-01 北京加科思新药研发有限公司 Fgfr4抑制剂的盐的晶型
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CN115504965A (zh) 2021-06-23 2022-12-23 浙江海正药业股份有限公司 嘧啶类衍生物的晶型及其制备方法
WO2023082044A1 (zh) * 2021-11-09 2023-05-19 暨南大学 5-醛基杂环酰胺类化合物及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
WO1998004554A1 (fr) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Antagonistes de recepteurs de chemokines
CN1284944A (zh) 1997-12-17 2001-02-21 麦克公司 整联蛋白受体拮抗剂
WO1999041239A1 (en) 1998-02-10 1999-08-19 Novartis Ag B cell inhibitors
AU7315700A (en) 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonist
SK8012002A3 (en) * 1999-11-08 2002-10-08 Merck & Co Inc Process for the preparation of imidazolidinone alfagammabeta3/alfagammabeta5 integrin antagonists and intermediates obtained by this method
JPWO2003068753A1 (ja) 2002-02-14 2005-06-02 小野薬品工業株式会社 Ｎ−カルバモイル窒素含有縮合環化合物およびその化合物を有効成分として含有する薬剤
US20060004010A1 (en) 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
JP2006512357A (ja) 2002-12-20 2006-04-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
AU2004220225B2 (en) 2003-03-14 2010-06-17 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
US7183413B2 (en) 2003-04-11 2007-02-27 Taigen Biotechnology Aminoquinoline compounds
JP4895811B2 (ja) 2003-09-11 2012-03-14 ケミア，インコーポレイテッド サイトカイン阻害剤
CN101223167B (zh) 2005-07-15 2011-08-31 弗·哈夫曼-拉罗切有限公司 杂芳基稠合的环状胺
KR101406956B1 (ko) * 2005-12-21 2014-06-13 노파르티스 아게 Ｆｇｆ 억제제로서의 피리미디닐 아릴 우레아 유도체
EP1976528A2 (en) 2005-12-29 2008-10-08 Janssen Pharmaceutica, N.V. Prokineticin 2 receptor antagonists
ES2582652T3 (es) 2006-02-10 2016-09-14 Genentech, Inc. Anticuerpos anti-FGF19 y métodos de uso de los mismos
BRPI0708731A2 (pt) 2006-03-10 2011-06-07 Ono Pharmaceutical Co derivado heterocìclico nitrogenado, e agente farmacêutico compreendendo o derivado como ingrediente ativo
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
KR20090119768A (ko) 2007-03-09 2009-11-19 노파르티스 아게 흑색종 치료법
EP3372237A1 (en) 2007-04-02 2018-09-12 Genentech, Inc. A klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
WO2009079008A1 (en) 2007-12-19 2009-06-25 Yangbo Feng Benzopyrans and analogs as rho kinase inhibitors
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
JP2012501637A (ja) 2008-09-03 2012-01-26 ライセンティア・リミテッド Ｆｇｆｒ４に関連する癌細胞浸潤を抑制するための材料および方法
US20110172217A1 (en) 2008-09-05 2011-07-14 Shionogi & Co., Ltd. Ring-fused morpholine derivative having pi3k-inhibiting activity
BRPI0918337A2 (pt) 2008-12-19 2017-05-30 Abbott Lab composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
MX2011011735A (es) 2009-05-04 2011-11-29 Plexxikon Inc Compuestos y metodos para la inhibicion de renina, e indicaciones para ello.
AU2010319842A1 (en) 2009-10-29 2012-05-17 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
EP2493864B1 (en) 2009-10-30 2014-10-01 Novartis AG N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
US20190192510A1 (en) 2010-02-01 2019-06-27 Nippon Chemiphar Co., Ltd. Gpr119 agonist
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
PT2598483T (pt) 2010-07-29 2020-10-12 Rigel Pharmaceuticals Inc Compostos heterocíclicos de ativação de ampk e métodos de utilização dos mesmos
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
BR112013023914A2 (pt) 2011-03-18 2016-12-13 Lupin Ltd derivados de benzo [b] [1,4] oxazina como moduladores de receptor sensor de cálcio
WO2012138975A1 (en) 2011-04-07 2012-10-11 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
GB201118656D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
RS62233B1 (sr) 2012-07-11 2021-09-30 Blueprint Medicines Corp Inhibitori receptora fibroblast faktora rasta
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2922572A1 (en) 2012-11-23 2015-09-30 AB Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
CN105307657B (zh) 2013-03-15 2020-07-10 西建卡尔有限责任公司 杂芳基化合物和其用途
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
TW201605452A (zh) 2013-08-28 2016-02-16 安斯泰來製藥股份有限公司 以嘧啶化合物作爲有效成分之醫藥組成物
DK3057943T3 (en) 2013-10-18 2018-07-30 Eisai R&D Man Co Ltd PYRIMIDINE-FGFR4 INHIBITORS
CN110028491B (zh) 2013-10-25 2022-02-11 缆图药品公司 纤维母细胞生长因子受体抑制剂

Also Published As

Publication number Publication date
PE20160546A1 (es) 2016-05-26
CA2927252C (en) 2021-09-28
SG11201602183QA (en) 2016-05-30
EP3060563A1 (en) 2016-08-31
EA201690848A1 (ru) 2016-08-31
AU2014338549A1 (en) 2016-04-14
MX367723B (es) 2019-09-03
US9266883B2 (en) 2016-02-23
JP6203954B2 (ja) 2017-09-27
BR112016008276B1 (pt) 2021-03-02
JP2017214411A (ja) 2017-12-07
WO2015059668A1 (en) 2015-04-30
CN105683188B (zh) 2018-02-09
US9533988B2 (en) 2017-01-03
PH12016500756A1 (en) 2016-05-30
AP2016009156A0 (en) 2016-04-30
KR101862493B1 (ko) 2018-05-29
AU2014338549B2 (en) 2017-05-25
US20160102092A1 (en) 2016-04-14
PL3060563T3 (pl) 2018-10-31
IL263404A (en) 2018-12-31
US9896449B2 (en) 2018-02-20
JP2016534072A (ja) 2016-11-04
IL244819A0 (en) 2016-05-31
NI201600058A (es) 2016-06-21
IL244819B (en) 2018-12-31
TR201810944T4 (tr) 2018-08-27
CR20160191A (es) 2016-07-01
DOP2016000094A (es) 2016-07-15
EA028819B1 (ru) 2018-01-31
AU2014338549A8 (en) 2016-04-21
CN105683188A (zh) 2016-06-15
EP3060563B1 (en) 2018-05-02
KR20160075644A (ko) 2016-06-29
CA2927252A1 (en) 2015-04-30
ES2682493T3 (es) 2018-09-20
US20170066766A1 (en) 2017-03-09
MX2019010446A (es) 2019-10-17
MX2016005394A (es) 2016-08-12
JP6429954B2 (ja) 2018-11-28
IL263404B (en) 2019-09-26
US20150119385A1 (en) 2015-04-30
PT3060563T (pt) 2018-07-26
JP6745856B2 (ja) 2020-08-26
TN2016000115A1 (en) 2017-07-05
JP2019031553A (ja) 2019-02-28
CL2016000922A1 (es) 2017-01-27
HK1222388A1 (zh) 2017-06-30

Similar Documents

Publication Publication Date Title
SV2016005186A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
SV2016005137A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2016000241A1 (es) Formulación de inhibidores de la syk.
PE20150887A1 (es) Compuestos de benceno sustituidos
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
CL2015002060A1 (es) Compuestos.
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
SV2016005313A (es) Derivados de carboxamida
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
UY35209A (es) Compuestos tricíclicos
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
BR112016023991A2 (pt) ativadores de herg policíclicos
UY35792A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CU20140127A7 (es) Moduladores de la ruta del complemento y usos de los mismos
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos